Date: 2013-11-19
Type of information: Initiation of patient enrollment
phase: 2
Announcement: recruitment of the firt patient
Company: Atopix Therapeutics (UK)
Product: OC459
Action
mechanism: Genetic variants in CRTH2 predispose patients to the development of atopic dermatitis. As a CRTH2 antagonist, OC459 has demonstrated in pre-clinical studies that it suppresses the recruitment and production of key cells that mediate an allergic response such as Th2 lymphocytes, basophils and eosinophils, resulting in reduced disease pathology. It is anticipated that patients with a highly atopic Th2 dominant form of eczema, who typically have a more severe form of the disease and are prone to flares, will benefit from treatment with OC459.
Disease: atopic dermatitis
Therapeutic area: Dermatological diseases - Immunological diseases - Inflammatory diseases
Country: UK, Germany, Austria, France and Finland
Trial details:
Latest
news: * On November 2013, Atopix Therapeutics, a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, has announced the recruitment of the first patient in a six month Phase 2 clinical trial of its lead compound OC459 in moderate-to-severe atopic dermatitis (eczema).
OC459 is designed as a once daily oral treatment. The first patient in this randomised, double-blind, placebo-controlled study was dosed at the University of Sheffield Medical Centre, United Kingdom. The clinical study is funded by a grant from the Biomedical Catalyst fund and incorporates other leading dermatology centres in the UK, Germany, Austria, France and Finland which will initiate dosing shortly.
The study aims to detect an effect of OC459 on flares, the major health economic burden in atopic dermatitis. The primary endpoint of the study will be judged against the Eczema Activity Severity Index (EASI), a score which measures the extent and severity of atopic dermatitis.
